Woojin B&G Reports Standalone Operating Profit of 1.7 Billion KRW in H1, Up 126% Year-on-Year

by Ryu Hyunseok

Published 14 Aug.2025 17:13(KST)

Woojin B&G, a company specializing in veterinary pharmaceuticals, announced on August 14 that it recorded an operating profit of 1.7 billion KRW on a standalone basis in the first half of this year, marking a 126% increase compared to the same period last year.

During the same period, sales reached 16.1 billion KRW, up 19% year-on-year. On a consolidated basis, sales were 28.1 billion KRW and operating profit was 600 million KRW.

A Woojin B&G representative explained, "Vaccine sales increased significantly overall, and export performance also rose by 20% compared to last year. In contrast, the cost of goods sold ratio continued to improve, resulting in a notable increase in operating profit."

The representative added, "The PED-M vaccine for porcine epidemic diarrhea is expected to receive overseas regulatory approval soon in countries such as Mexico and Vietnam. We also anticipate export performance exceeding 10 billion KRW by the end of the second half."